For example, while we observed some evidence that women with insomnia symptoms and ER + /PR + had increased survival if they received no chemotherapy or aromatase inhibitors, compared to women on other chemotherapy, these subgroup analyses were extremely imprecise and therefore we cannot infer the effects of treatment-induced sleep disruption on breast cancer survival. Here, CYP19A1 is linked to insomnia measurement.